We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Inozyme Pharma Inc (INZY) USD0.0001

Sell:$9.25 Buy:$9.29 Change: $0.20 (2.12%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Sell:$9.25
Buy:$9.29
Change: $0.20 (2.12%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
Sell:$9.25
Buy:$9.29
Change: $0.20 (2.12%)
Market closed |  Prices as at close on 15 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

Contact details

Address:
321 SUMMER STREET, SUITE 400
BOSTON
02210
United States
Telephone:
+1 (857) 3304340
Website:
www.inozyme.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
INZY
ISIN:
US45790W1080
Market cap:
$230.23 million
Shares in issue:
23.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Axel Bolte
    President, Chief Executive Officer, Director
  • Stephen Dipalma
    Interim Chief Financial Officer, Principal Chief Accounting Officer
  • Henric Bjarke
    Chief Operating Officer, Senior Vice President
  • Steven Jungles
    Senior Vice President, Chief Technical Operations Officer
  • Gayle Gironda
    Senior Vice President of Human Resources
  • Deborah Wenkert
    Senior Vice President, Chief medical officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.